In the presence of Ex9, the acute effects of myricetin were dose-dependently reduced, including the decrease of hyperglycemia (Figure 1d), the higher plasma BER (Figure 1e) and increased plasma adropin levels (Figure 1f). This evidence concerns the gene ENHO and Hyperglycemia.